Analysts Have Conflicting Sentiments on These Healthcare Companies: Sangamo Biosciences (NASDAQ: SGMO) and Neurocrine (NASDAQ: NBIX)

By Austin Angelo

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Sangamo Biosciences (NASDAQ:SGMO) and Neurocrine (NASDAQ:NBIX).

Sangamo Biosciences (SGMO)

In a report released today, Liana Moussatos from Wedbush reiterated a Hold rating on Sangamo Biosciences, with a price target of $9. The company’s shares opened today at $14.50.

According to TipRanks.com, Moussatos is a 4-star analyst with an average return of 7.6% and a 43.7% success rate. Moussatos covers the Healthcare sector, focusing on stocks such as Allena Pharmaceuticals Inc, Catabasis Pharmaceuticals, and Global Blood Therapeutics.

Currently, the analyst consensus on Sangamo Biosciences is a Moderate Buy with an average price target of $18.50.

See today’s analyst top recommended stocks >>

Neurocrine (NBIX)

In a report released today, Alan Carr from Needham assigned a Buy rating to Neurocrine, with a price target of $110. The company’s shares opened today at $105.14, close to its 52-week high of $107.57.

Carr noted:

“Neurocrine and collaborator Abbvie announced approval of Orilissa (elagolix) for the management of moderate to severe pain associated with Endometriosis. Abbvie is guiding for the drug to be available in early August. According to Neurocrine mgmt, WAC price is $844.87/ mo for both 150mg QD regimen and 200mg BID regimen. Max treatment duration is 24mo for former and 6mo for latter. We are not making any material changes to our Orilissa sales ests. Neurocrine is entitled to a $40M approval milestone payment in 3Q18 and tiered royalties, which we believe range from 16-20%. Reiterate BUY.”

According to TipRanks.com, Carr is a 4-star analyst with an average return of 4.1% and a 41.9% success rate. Carr covers the Healthcare sector, focusing on stocks such as Biohaven Pharmaceutical Holding Co Ltd, Rhythm Pharmaceuticals Inc, and Lexicon Pharmaceuticals.

Currently, the analyst consensus on Neurocrine is a Strong Buy with an average price target of $109.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.